Novartis’ Itvisma Receives the CHMP Positive Opinion for Spinal Muscular Atrophy

Why It Matters

The CHMP endorsement clears a major regulatory hurdle, positioning Itvisma to expand the limited SMA gene‑therapy options and potentially capture a significant share of a high‑growth market.

Key Takeaways

• CHMP gave positive opinion for Itvisma in SMA patients aged ≥2.
• STEER trial showed 2.39‑point HFMSE gain versus 0.51 for sham.
• Single intrathecal dose delivers functional SMN1 gene for sustained protein.
• Benefits observed in both treatment‑naïve and previously treated patients.
• Itvisma could capture sizable share of the growing SMA gene‑therapy market.

Pulse Analysis

Spinal muscular atrophy remains one of the most severe neuromuscular disorders, affecting roughly 1 in 10,000 newborns worldwide. The disease stems from loss of the SMN1 gene, leading to progressive muscle weakness and early mortality. Over the past decade, gene‑replacement therapies have transformed the therapeutic landscape, offering the promise of durable motor function improvement. Yet, the market is still dominated by a handful of products, and clinicians continue to seek options that address broader patient sub‑groups, especially those older than two years.

Novartis’ Itvisma leverages an adeno‑associated viral vector to introduce a functional SMN1 copy directly into the central nervous system via a single intrathecal infusion. The pivotal STEER Phase III trial demonstrated a statistically significant 2.39‑point advantage on the HFMSE scale compared with sham, with the effect persisting through a full year. Complementary data from the STRENGTH Phase IIIb study reinforced efficacy across both treatment‑naïve and previously treated cohorts, underscoring the therapy’s versatility. The CHMP’s positive opinion not only validates the clinical data but also accelerates the pathway to European market entry, a critical step for a therapy targeting a rare, high‑unmet‑need indication.

From a commercial perspective, Itvisma enters a competitive arena that includes Zolgensma and other emerging gene‑therapy candidates. However, its focus on patients aged two and older expands the addressable population beyond infant‑only indications, potentially unlocking a multi‑billion‑dollar revenue stream. Pricing will likely reflect the high manufacturing costs typical of viral vector therapies, but reimbursement prospects are bolstered by the demonstrated long‑term functional gains. As payers evaluate cost‑effectiveness, Itvisma’s single‑dose regimen and sustained benefit could position it as a preferred option, influencing both market dynamics and future R&D investment in SMA treatments.